=> d ibib abs hitstr l26 1-48

L26 ANSWER 1 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:995776 HCAPLUS
TITLE: Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias with quinoline ring-containing neuromelanin-binding compounds
INVENTOR(S): Nelson, Jodi
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Ser. No. 192,414.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004229908	A1	20041118	US 2003-616692		20030709 <--
US 6417177	B1	20020709	US 2000-615639		20000713 <--
US 2002198231	A1	20021226	US 2002-192414		20020709 <--
PRIORITY APPLN. INFO.:			US 1999-143767P	P	19990713 <--
			US 2000-175051P	P	20000107 <--
			US 2000-202140P	P	20000505 <--
			US 2000-615639	A2	20000713 <--
			US 2002-192414	A2	20020709
			US 2003-479748P	P	20030619

AB This invention provides compns. and methods for increasing cellular respiration of melanized catecholamine neurons, and methods for alleviating symptoms or stopping appearance and/or progression of symptoms of Parkinson's disease and related conditions, characterized by nigrostriatal degeneration, as well as drug-induced dyskinesias, tardive dyskinesia, Neuroleptic Malignant Syndrome, and neg. symptoms of schizophrenia. An effective amount of a neuromelanin-binding composition having a quinoline ring in a suitable pharmaceutical carrier is administered to patient in need of such treatment. Preferably the composition comprises (-)-chloroquine diphosphate. Selected adjuvants are also provided as part of the compns. of this invention.

IT **116644-53-2**, Mibefradil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of parkinson's disease and tardive dyskinesias using neuromelanin-binding quinoline analogs and adjuvants such as cytochrome P 450 inhibitors and dopamine modulators)
RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 2 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:473189 HCAPLUS
DOCUMENT NUMBER: 141:35979
TITLE: Ion channel assay methods using repetitive application of electric fields to set transmembrane potential
INVENTOR(S): Maher, Michael P.; Gonzalez, Jesus E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 95 pp., Cont.-in-part of U.S. Pat. Appl. 2002 45,159.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 2004110123	A1	20040610	US 2003-620312		20030714	<--
US 2002045159	A1	20020418	US 2001-804457		20010312	<--
PRIORITY APPLN. INFO.:			US 2000-217671P	P	20000710	<--
			US 2001-804457	A2	20010312	<--

AB A method of characterizing the biol. activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of elec. fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel. A 96 well plate assay was developed for antagonists of the L-type calcium channel that incorporates elec. stimulation in the presence of DISBAC2(3) and CC2-DMPE voltage-sensitive FRET probes.

IT **116644-53-2**, Mibefradil
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ion channel assay methods using repetitive application of elec. fields to set transmembrane potential)

RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 3 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:451474 HCAPLUS
DOCUMENT NUMBER: 141:1258
TITLE: Nitrosated compounds in methods of treating vascular diseases characterized by nitric oxide insufficiency
INVENTOR(S): Loscalzo, Joseph; Vita, Joseph A.; Loberg, Michael D.; Worcel, Manuel
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 679,257.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 2004105850	A1	20040603	US 2003-692724		20031027	<--
US 6635273	B1	20031021	US 2000-697317		20001027	<--
US 2004071766	A1	20040415	US 2003-679257		20031007	<--
PRIORITY APPLN. INFO.:			US 1999-162230P	P	19991029	<--
			US 2000-179020P	P	20000131	<--
			US 2000-697317	A1	20001027	<--
			US 2003-679257	A2	20031007	

OTHER SOURCE(S): MARPAT 141:1258
AB The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress. Nitric oxide action was shown to be impaired in the microvasculature of black hypertensive patients to a greater extent than in white hypertensive

patients.

IT **116644-53-2D**, Mibefradil, nitrosated compds.
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrosated compds. in methods of treating vascular diseases characterized by nitric oxide insufficiency)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 4 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:269863 HCAPLUS

DOCUMENT NUMBER: 140:281417

TITLE: Combination therapy using antihypertensive agents and endothelin antagonists for vascular conditions associated with a male or female sexual dysfunction

INVENTOR(S): Adams, Michael A.; Hale, Taben M.; Heaton, Jeremy P. W.

PATENT ASSIGNEE(S): Queen's University At Kingston, Can.; Callegy Pharmaceuticals, Inc.

SOURCE: U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Pat. Appl. 2003 8,020.
CODEN: USXXCO

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 2004063719	A1	20040401	US 2003-429197		20030502	<--
US 6284763	B1	20010904	US 1999-382749		19990825	<--
US 2002035067	A1	20020321	US 2001-902787		20010712	<--
US 6458797	B2	20021001				
US 2003008020	A1	20030109	US 2002-192281		20020709	<--
US 6787553	B2	20040907				
US 2004234619	A1	20041125	US 2004-869755		20040615	<--
PRIORITY APPLN. INFO.:			US 1998-98178P	P	19980826	<--
			US 1999-382749	A1	19990825	<--
			US 2001-902787	A1	20010712	<--
			US 2002-377917P	P	20020502	
			US 2002-192281	A2	20020709	

AB The present invention provides a method for a more efficacious treatment of a vascular condition through the administration of a therapeutically effective amount of a combination of an anti-pressor agent, an endothelin antagonist, and a sex hormone for repetitive cycles of on/off-treatment.

In one embodiment, the invention provides a method for the prevention of tolerance induced by an anti-pressor agent via the inclusion of an endothelin antagonist in a combination therapy approach to remodel vascular structure and treat vascular conditions associated with a male or female sexual dysfunction, atherosclerosis, renal failure, hypertension, congestive heart failure, diabetic nephropathy, and diabetic neuropathy. The anti-pressor agent comprises one or more compds. such as prostaglandin-E 1 , an ACE inhibitor, an angiotensin-II receptor antagonist, an α1-adrenergic receptor antagonist, a β-adrenergic receptor antagonist, a calcium channel blocker, an activator of guanylyl cyclase or adenyl cyclase, a phosphodiesterase inhibitor, and hydralazine. The endothelin antagonist comprises one or more compds. such as a peptidal endothelin antagonist, a non-peptidal endothelin antagonist, and an inhibitor of endothelin converting enzyme. Such a combination therapy approach enhances the efficacy of the anti-pressor agent and enables an increase in the frequency and duration of anti-pressor administrations for the long term treatment of vascular conditions.

IT **116644-53-2**, Mibefradil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy using antihypertensive agents and endothelin antagonists for vascular conditions associated with a male or female sexual dysfunction)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 5 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:41228 HCAPLUS
DOCUMENT NUMBER: 140:105304
TITLE: Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
INVENTOR(S): Nelson, Jodi
PATENT ASSIGNEE(S): Alpha Research Group, L.L.C., USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004660	A2	20040115	WO 2003-US21463	20030709

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002198231	A1	20021226	US 2002-192414		20020709 <--
PRIORITY APPLN. INFO.:			US 2002-192414	A	20020709
			US 2003-479748P	P	20030619
			US 1999-143767P	P	19990713 <--
			US 2000-175051P	P	20000107 <--
			US 2000-202140P	P	20000505 <--
			US 2000-615639	A2	20000713 <--

AB This invention provides compns. and methods for increasing cellular respiration of melanized catecholamine neurons, and methods for alleviating symptoms or stopping appearance and/or progression of symptoms of Parkinson's disease and related conditions, characterized by nigrostriatal degeneration, as well as drug-induced dyskinesias, tardive dyskinesia, Neuroleptic Malignant Syndrome, and neg. symptoms of schizophrenia. An effective amount of a neuromelanin-binding composition having a quinoline ring in a suitable pharmaceutical carrier is administered to patient in need of such treatment. Preferably the composition comprises (-)-chloroquine diphosphate. Selected adjuvants are also provided as part of the compns. of this invention.

IT **116644-53-2**, Mibefradil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for treatment of Parkinson's disease and tardive dyskinesias)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 6 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	2003:678514 HCAPLUS
DOCUMENT NUMBER:	139:191440
TITLE:	Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
INVENTOR(S):	Krul, Elaine S.
PATENT ASSIGNEE(S):	USA
SOURCE:	U.S. Pat. Appl. Publ., 32 pp. CODEN: USXXCO
DOCUMENT TYPE:	**Patent**
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003162824	A1	20030828	US 2002-292255		20021112 <--
PRIORITY APPLN. INFO.:			US 2001-331346P	P	20011112 <--
			US 2001-338291P	P	20011113 <--

OTHER SOURCE(S): MARPAT 139:191440

AB Methods for treating or preventing one or more cardiovascular conditions in a subject comprises treating the subject with a therapeutically effective amount of a selective cyclooxygenase-1 inhibitor or a pharmaceutically-acceptable salt, tautomer or prodrug thereof alone or in combination with either a drug used in the treatment or prevention of a cardiovascular condition or a non-drug therapy used in the treatment of a cardiovascular condition. Cyclooxygenase-1 inhibitor, 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)pyrazole (I), was prepared from 4'-chloroacetophenone and (4-methoxyphenyl)hydrazine hydrochloride. I inhibited development of atherosclerosis in cholesterol-fed apoE knockout mice.

IT **116644-53-2**, Mibefradil
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium channel blocker; cyclooxygenase-1 inhibitor for treating or preventing cardiovascular conditions)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 7 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:355819 HCAPLUS
DOCUMENT NUMBER: 138:348731
TITLE: Modulators of small-conductance, calcium-activated potassium (SK) channels and T-type calcium channels, and therapeutic use
INVENTOR(S): Wolfart, Jakob; Roeper, Jochen
PATENT ASSIGNEE(S): Fr.
SOURCE: U.S. Pat. Appl. Publ., 57 pp.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2003087799 A1 20030508 US 2002-216128 20020809 <--
CA 2397005 AA 20030507 CA 2002-2397005 20020807 <--
WO 2003039449 A2 20030515 WO 2002-GB4880 20021030 <--
WO 2003039449 A3 20040415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1465609 A2 20041013 EP 2002-770126 20021030 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
PRIORITY APPLN. INFO.: GB 2001-26781 A 20011107 <--
US 2002-216128 A 20020809
WO 2002-GB4880 W 20021030

AB A method of treatment is described. The inventors have found that preferential coupling of small-conductance, calcium-activated potassium (SK) channels to T-type calcium channels prevents bursting in dopaminergic midbrain neurons. The treatment method comprises administering an agent which is capable of causing a dopaminergic neuron to enter bursting mode and/or of preventing it from leaving bursting mode. In a preferred aspect, the agent modulates a T-type channel and/or an SK (preferably SK3) channel and/or the coupling of a T-type channel with an SK (preferably SK3) channel. The invention is useful in the treatment of e.g. Parkinson's disease.

IT **116644-53-2**, Mibefradil
RL: PAC (Pharmacological activity); BIOL (Biological study)
(modulators of small-conductance, calcium-activated potassium (SK) channels and T-type calcium channels, and therapeutic use)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 8 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:355625 HCAPLUS
DOCUMENT NUMBER: 138:331719
TITLE: Method for the suppression of visceral pain by regulating T type calcium channel
INVENTOR(S): Shin, Hee-Sup; Kim, Dae-Soo; Kim, Chan-Ki
PATENT ASSIGNEE(S): S. Korea
SOURCE: U.S. Pat. Appl. Publ., 9 pp.

CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003086980	A1	20030508	US 2002-284889	20021031 <--
KR 2003037081	A	20030512	KR 2001-68180	20011102 <--
JP 2003137813	A2	20030514	JP 2002-310392	20021025 <--
EP 1312362	A1	20030521	EP 2002-257625	20021104 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.: KR 2001-68180 A 20011102 <--

AB The disclosure concerns a method for the suppression of visceral pain by regulating the T-type calcium channel; a visceral pain inhibitor that includes a T-type calcium channel inhibitor as an effective ingredient; and a method of screening a visceral pain inhibitor by investigating the suppression activity of T-type calcium channels. Particularly, the present invention relates to a method for the suppression of visceral pain by regulating an alpha 1G T-type calcium channel in the central nervous system and alpha 1H and alpha 1I T-type calcium channels in the peripheral nervous system; a visceral pain inhibitor that includes a T-type calcium channel inhibitor as an effective ingredient; and a method of screening a visceral pain inhibitor by investigating the suppression activity of T-type calcium channels. The method of the present invention can be effectively used to suppress visceral pain by regulating T-type calcium channel in a precise mechanism without any side effects. Mibefradil induced analgesia to the visceral pain caused by acetic acid in mice.

IT **116644-53-2**, Mibefradil
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as T-type calcium channel inhibitor; suppression of visceral pain by regulating T type calcium channel)

RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 9 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:335151 HCAPLUS
DOCUMENT NUMBER: 138:348729
TITLE: Method for resistance of epilepsy by suppressing the function of alpha 1G protein
INVENTOR(S): Shin, Hee-Sup; Kim, Daesoo; Keum, Sehoon; Song, Inseon
PATENT ASSIGNEE(S): Bio Genomics, Inc., S. Korea; Pohang University of

Science and Technology
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035698	A1	20030501	WO 2002-KR87	20020118 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2003034605	A	20030509	KR 2001-66257	20011026 <--
PRIORITY APPLN. INFO.:			KR 2001-66257 A	20011026 <--

AB The disclosure concerns a method for resistance of epilepsy by suppressing the function of alpha 1G protein of T-type calcium channels, use of suppressor of alpha 1G protein for prevention or treatment for epilepsy, knockout mice resisting epilepsy by disrupting alpha 1G subunit of T-type calcium channel, and preparation method thereof. In addition, suppressing alpha 1G protein of T-type calcium channels does not occur epilepsy, and alpha 1G-deficient mice are useful to study of mechanism related to epilepsy.

IT **116644-53-2**, Mibefradil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for resistance of epilepsy by suppressing the function of alpha 1G protein)

RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 10 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:301058 HCAPLUS
DOCUMENT NUMBER: 138:297661
TITLE: Mibefradil-based compounds as calcium channel blockers

useful in the treatment of hypertension and angina

INVENTOR(S): Druzgala, Pascal; Milner, Peter G.; Pfister, Jurg R.; Zhang, Xiaoming

PATENT ASSIGNEE(S): Aryx Therapeutics, USA

SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003031415	A1	20030417	WO 2002-US32562	20021010 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003130330	A1	20030710	US 2002-269139	20021010 <--
US 6608097	B2	20030819		
EP 1438297	A1	20040721	EP 2002-773743	20021010 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2004034237	A1	20040219	US 2003-643699	20030818 <--

PRIORITY APPLN. INFO.:			
US 2001-328588P	P	20011010 <--
US 2002-269139	A1	20021010
WO 2002-US32562	W	20021010

OTHER SOURCE(S): MARPAT 138:297661

GI



I



II

Searched by P. Ruppel

AB The invention provides mibefradil-based calcium channel blockers I [X = bond, (CH2)n, O, S, O(CH2)n (n = 1-6); R1 = C1-6 alkyl, optionally substituted with OH or NH2; R2 = F, COOR5 (R5 = R1); R3 = CH3, (CH2)nCOOR6, (n = 1-6; R6 = R1); R4 = (CH2)nCOR7R8, (CH2)nR10R11, Q1; R7 = O, NH, NR9, R8 = optionally substituted aryl or heterocyclyl; R9 = C1-6 alkyl; R10 = O, S, SO, SO2, NH, NR12, N(CH2)mCOOR13; R11 = aryl or heterocyclyl optionally substituted with (CH2)nCOOR14, R12-R14 = R1; R15 = (CH2)n COOR16, R16 = R1; R17 = absent or COOR18; R18 = R1; n = 1-6] useful in the treatment of hypertension, angina pectoris, ischemia, arrhythmias and cardiac insufficiency.

IT **116644-53-2D**, Mibefradil, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mibefradil-based compds. as calcium channel blockers for treatment of hypertension and angina)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 11 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:300530 HCAPLUS
DOCUMENT NUMBER: 138:314620
TITLE: Calcium channel multibinding drugs, and uses
INVENTOR(S): Ji, Yu-Hua; Natarajan, Maya; Griffin, John H.; Jenkins, Thomas E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 183 pp., Cont.-in-part of U.S. Ser. No. 325,557, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003073127	A1	20030417	US 1999-456429	19991208 <--
CA 2318806	AA	19991216	CA 1999-2318806	19990607 <--
CA 2319142	AA	19991216	CA 1999-2319142	19990607 <--
CA 2319153	AA	19991216	CA 1999-2319153	19990607 <--
WO 9963984	A1	19991216	WO 1999-US11801	19990607 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 9963932	A2	19991216	WO 1999-US12724	19990607	<--
WO 9963932	A3	20000203			

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 9964045	A1	19991216	WO 1999-US12754	19990607	<--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9945511	A1	19991230	AU 1999-45511	19990607	<--
AU 9946726	A	19991230	AU 1999-46726	19990607	<--
EP 1085879	A2	20010328	EP 1999-928442	19990607	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

EP 1085890	A1	20010328	EP 1999-930122	19990607	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

EP 1089749	A1	20010411	EP 1999-928447	19990607	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

JP 2002517437	T2	20020618	JP 2000-553053	19990607	<--
ZA 2000004562	A	20011130	ZA 2000-4562	20000831	<--
ZA 2000004563	A	20011130	ZA 2000-4563	20000831	<--
ZA 2000004564	A	20011130	ZA 2000-4564	20000831	<--
US 2003044845	A1	20030306	US 2002-75017	20020213	<--
US 2004242561	A1	20041202	US 2004-877368	20040625	<--

PRIORITY APPLN. INFO.:	US 1998-88465P	P	19980608	<--
	US 1998-93068P	P	19980716	<--
	US 1998-103866P	P	19981012	<--
	US 1999-325557	B2	19990604	<--
	US 1999-327096	B1	19990607	<--
	WO 1999-US11801	W	19990607	<--
	WO 1999-US12724	W	19990607	<--
	WO 1999-US12754	W	19990607	<--
	US 1999-456429	A1	19991208	<--
	US 2000-499176	B1	20000207	<--

OTHER SOURCE(S): MARPAT 138:314620

AB Multibinding compds. are disclosed. The compds. of the invention comprise 2-10 ligands covalently connected via linker groups, each of the ligands being capable of binding to a ligand-binding site in a calcium channel, thereby modulating the biol. activities thereof. The compds. of the

invention may be used to treat diseases or conditions resulting from calcium channel activity. Pharmaceutical compns. are also disclosed.

IT **116644-53-2D**, Mibefradil, ligand-linker conjugates
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium channel multibinding drugs, and uses)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 12 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:300513 HCAPLUS
DOCUMENT NUMBER: 138:297607
TITLE: Computational technique-based drug rescue by redesign of ADMET/PK properties
INVENTOR(S): Selick, Harold E.; Korzekwa, Kenneth R.; Mackarehtschian, Katrin
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003073069	A1	20030417	US 2001-978671	20011015 <--
WO 2003034065	A2	20030424	WO 2002-US32873	20021015 <--
WO 2003034065	A3	20040624		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-978671 A 20011015 <--

AB Otherwise efficacious drugs having an ADMET/PK (absorption, distribution, metabolism, elimination, toxicity, i.e., pharmacokinetic) problem are redesigned or "rescued" by applying computational techniques that identify related chemical structures that preserve the initial drug's effectiveness but improve its ADMET/PK properties. The otherwise efficacious drug may

be subjected to a suite of computational tools that identify sites responsible for problematic ADMET/PK properties and/or identify related compds. that have improved ADMET/PK properties.

IT **116644-53-2**, Mibefradil
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(computational technique-based drug rescue by redesign of ADMET/PK properties)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 13 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:222330 HCAPLUS
DOCUMENT NUMBER: 138:215346
TITLE: Method for treating a demyelinating condition
INVENTOR(S): Werner, Peter; Pitt, David; Brand-Schieber, Elimor
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. 6,455,553.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003055036	A1	20030320	US 2002-223068	20020816 <--
US 6455553	B1	20020924	US 2000-678686	20001003 <--
PRIORITY APPLN. INFO.:			US 2000-678686 A2	20001003 <--

AB Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca2+ channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of a glutamate inhibitor effective to treat the demyelinating condition. In addnl. aspects, the methods encompass administering to the subject a Ca2+ channel blocker in combination with a glutamate inhibitor, in amts. effective to treat the demyelinating condition. In still other aspects, the methods encompass administering to the subject a Ca2+ channel blocker in combination with a hypertensive agent, in amts. effective to treat the demyelinating condition. Also provided are pharmaceutical compns. having a Ca2+ channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier. Addnl., pharmaceutical compns. having a Ca2+ channel blocker, a hypertensive agent, and a pharmaceutically-acceptable carrier are

provided.

IT **116644-53-2**, Mibefradil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treating a demyelinating condition)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 14 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:133047 HCAPLUS
DOCUMENT NUMBER: 138:163518
TITLE: Improved treatment of cancer with irinotecan based on genotyping of human gene CYP3A5 encoding cytochrome P 450 3A5
INVENTOR(S): Heinrich, Guenther; Kerb, Reinhold
PATENT ASSIGNEE(S): Epidauros Biotechnologie AG, Germany
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013534	A2	20030220	WO 2002-EP8219	20020723 <--
WO 2003013534	A3	20031009		
WO 2003013534	C2	20040429		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1408975	A2	20040421	EP 2002-767255	20020723 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.:	EP 2001-117608	A	20010723 <--
	EP 2002-11710	A	20020524
	WO 2002-EP8219	W	20020723

AB The present invention relates to the use of irinotecan or a derivative thereof

for the preparation of a pharmaceutical composition for treating colorectal cancer,
cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with variant alleles of genes involved in irinotecan metabolism, and in particular gene CYP3A5 encoding cytochrome P 450 3A5. Irinotecan (CPT-11) is an analog of the cytotoxic alkaloid camptothecin and is a prodrug of the lipophilic metabolite SN-38 (7-ethyl-10-hydroxycamptothecin). Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of the variant allele compared to the corresponding wild-type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild-type allele. Irinotecan dosage is calculated based on genotype correlated with the risk of toxic reaction.

IT **116644-53-2**, Mibefradil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CYP3A5 inhibitor; improved treatment of cancer with irinotecan based on genotyping of human gene CYP3A5 encoding cytochrome P 450 3A5)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 15 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:76615 HCAPLUS
DOCUMENT NUMBER: 138:117667
TITLE: Methods and compositions for modulating T-type calcium channels
INVENTOR(S): Romano, Carmelo; Todorovic, Slobodan M.; Zorumski, Charles F.
PATENT ASSIGNEE(S): Washington University, USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003007953	A1	20030130	WO 2002-US22890	20020718 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,

TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-306298P P 20010718 <--

AB The invention discloses methods and compns. for the modulation of activity of T-type calcium 2+ channels. Described is a method for treatment, inhibition or prevention of pain perception in a subject in need thereof comprising administering to the subject an amount of an inhibitor of T-type Ca2+ channel activity or a pharmaceutically acceptable salt or prodrug thereof effective to treat, inhibit or prevent pain perception in the subject.

IT **116644-53-2**, Mibefradil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for modulating T-type calcium channels)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 16 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:978470 HCAPLUS
DOCUMENT NUMBER: 138:33365
TITLE: Compositions and methods for the treatment of Parkinson's disease with quinoline ring-containing neuromelanin-binding compounds
INVENTOR(S): Nelson, Jodi
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. 6,417,177.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002198231	A1	20021226	US 2002-192414	20020709 <--
US 6417177	B1	20020709	US 2000-615639	20000713 <--
WO 2004004660	A2	20040115	WO 2003-US21463	20030709

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004229908	A1	20041118	US 2003-616692		20030709 <--
PRIORITY APPLN. INFO.:			US 1999-143767P	P	19990713 <--
			US 2000-175051P	P	20000107 <--
			US 2000-202140P	P	20000505 <--
			US 2000-615639	A2	20000713 <--
			US 2002-192414	A	20020709
			US 2003-479748P	P	20030619

AB This invention provides compns. and methods for increasing cellular respiration of melanized catecholamine neurons, and methods for alleviating symptoms or stopping appearance and/or progression of symptoms of Parkinson's disease and related conditions, characterized by nigrostriatal degeneration. An effective amount of a neuromelanin-binding composition having a quinoline ring in a suitable pharmaceutical carrier is administered to patient in need of such treatment. Preferably the composition comprises (-)-chloroquine. Selected adjuvants are also provided as part of the compns. of this invention.

IT **116644-53-2**, Mibefradil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cytochrome P 450 2D6 inhibitor inhibiting peripheral metabolism of chloroquine compds.; quinoline ring-containing neuromelanin-binding compds. for treatment of Parkinson's disease)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 17 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	2002:778718 HCAPLUS
DOCUMENT NUMBER:	137:289046
TITLE:	Methods and compositions for enhancing pharmaceutical treatments
INVENTOR(S):	Newman, Michael J.; Dixon, William Ross
PATENT ASSIGNEE(S):	USA
SOURCE:	U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 684,293. CODEN: USXXCO
DOCUMENT TYPE:	**Patent**
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002147197	A1	20021010	US 2002-104549		20020320 <--
PRIORITY APPLN. INFO.:			US 1999-158322P	P	19991008 <--
			US 2000-684293	A2	20001006 <--

OTHER SOURCE(S): MARPAT 137:289046

AB Improved methods are provided for therapeutic and/or preventative treatment to a mammal in which the mammal is protected against the toxicity of active pharmaceutical agents that (i) bind to or are substrates for P-gp, (ii) are taxane analogs, and/or (iii) are inhibitors of tubulin disassembly. Addnl. provided are compns. and methods useful for treating cell proliferative disorders. Further provided are methods of increasing the bioavailability of therapeutic and/or preventative treatments in a mammal. Particular embodiments are directed to increasing such bioavailability across the blood-brain barrier.

IT **116644-53-2**, Mibefradil **116644-53-2D**, Mibefradil, derivs., analogs, and metabolites
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for enhancing pharmaceutical treatments)

RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 18 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:574927 HCAPLUS

DOCUMENT NUMBER: 137:119655
TITLE: Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
INVENTOR(S): Borisy, Alexis; Keith, Curtis; Foley, Michael A.; Stockwell, Brent R.
PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058697	A1	20020801	WO 2002-US1707	20020122 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002165261	A1	20021107	US 2001-768870	20010124 <--
US 6693125	B2	20040217		
EP 1363625	A1	20031126	EP 2002-709117	20020122 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004063769	A1	20040401	US 2003-677664	20031002 <--
PRIORITY APPLN. INFO.:			US 2001-768870 A1	20010124 <--
			WO 2002-US1707 W	20020122

OTHER SOURCE(S): MARPAT 137:119655

AB The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (1) a benzimidazole or a metabolite or analog thereof; and (ii) pentamidine or a metabolite or analog thereof simultaneously or within 14 days of each other in amts. sufficient to inhibit the growth of the neoplasm.

IT **116644-53-2**, Mibefradil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug combinations for treatment of neoplastic disorders)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Searched by P. Ruppel

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 19 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:916407 HCAPLUS
DOCUMENT NUMBER: 136:53755
TITLE: Synthesis of nitrosated and nitrosylated (hetero)cyclic phosphodiesterase inhibitors used in treatment of sexual dysfunction
INVENTOR(S): Garvey, David S.; Saenz de Tejada, Inigo; Earl, Richard A.; Khanapure, Subhash P.
PATENT ASSIGNEE(S): Nitromed, Inc., USA
SOURCE: U.S., 117 pp., Cont.-in-part of U.S. 5,958,926. CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6331543	B1	20011218	US 1999-387727	19990901 <--
US 5874437	A	19990223	US 1996-740764	19961101 <--
WO 9819672	A1	19980514	WO 1997-US19870	19971031 <--
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5958926	A	19990928	US 1998-145142	19980901 <--
US 2002019405	A1	20020214	US 2001-941691	20010830 <--
US 6462044	B2	20021008		
US 2003023087	A1	20030130	US 2002-216886	20020813 <--
US 2004087591	A1	20040506	US 2003-694183	20031028 <--

PRIORITY APPLN. INFO.:

US 1996-740764	A2	19961101 <--
WO 1997-US19870	A2	19971031 <--
US 1998-145142	A2	19980901 <--
US 1999-387727	A1	19990901 <--
US 2001-941691	A3	20010830 <--
US 2002-216866	A3	20020813

OTHER SOURCE(S): MARPAT 136:53755
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. I-V, derivs. thereof, and certain substituted Ph and phthalzaine derivs. were claimed [D2 = H, alkyl, D; D = NO, NO2, alkyl, acyl, phosphoryl, silyl, etc.; A1-3 comprise the other subunits of a 5- or 6-membered monocyclic aromatic ring; R8 = H, (halo)alkyl; p = 1-10; R24 = H, cyclohexyl, piperidinyl, etc., with the proviso that at least one of A1-3, J, or R24 contains T-Q or D; T = bond, O, S(O), amino; Q = NO, NO2; D1 = D or H; R37 = (hetero)aryl; R38 = H, halo, alkyl; G1 = alkyl, alkenyl or is part of a ring fused to the piperidine moiety of III; G4 = O, S; R40 = H, alkyl, haloalkyl, halo, etc.; R41 = alkyl, hydroxyalkyl, alkylcarboxy, etc.; R42 = aryl, alkylaryl, alkyloxyaryl; T1 = alkyl, oxyalkyl, thioalkyl, aminoalkyl]. Two synthetic examples were provided. E.g., the S-nitroso derivative of the 3-mercapto-3-methylbutyric acid ester of dipyridamole (VI) was prepared in 4 steps from dipyridamole in 3.5% overall yield. VI at doses of 10 and 30 μM was more efficacious in relaxing

phenylephrine-induced tissue contraction than was the known phosphodiesterase inhibitor, dipyridamole. The present invention describes novel (nitrosated/nitrosylated) phosphodiesterase inhibitors, and compns. containing at least one (nitrosated/nitrosylated) phosphodiesterase inhibitor, and, optionally, one or more compds. that donate, transfer or release NO, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of NO, or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of cGMP, such as hypertension, pulmonary hypertension, etc.

IT **116666-63-8D**, Posicor, nitroso derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthesis of nitrosated and nitrosylated (hetero)cyclic phosphodiesterase inhibitors used in treatment of sexual dysfunction)

RN 116666-63-8 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 20 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:833855 HCAPLUS
DOCUMENT NUMBER: 135:352760
TITLE: Inhibition of taxane metabolism
INVENTOR(S): Synold, Timothy W.; Doroshow, James H.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2001041706	A1	20011115	US 2001-814072		20010322 <--
PRIORITY APPLN. INFO.:			US 2000-191828P	P	20000324 <--

AB Methods are disclosed for the inhibition of taxane metabolism in patients receiving anticancer taxane treatment, in which an effective amount of a CYP3A4 inhibitor and a CYP2C8 inhibitor are administered to the patient.

IT **116644-53-2**, Mibefradil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of taxane metabolism)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 21 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:636058 HCAPLUS
DOCUMENT NUMBER: 135:211039
TITLE: Preparation of tetrahydronaphthalene derivatives for use in therapy of type 1 and type 2 diabetes
INVENTOR(S): Li, Ming; Hansen, John Bondo; Tagmose, Tina Moller
PATENT ASSIGNEE(S): South Alabama Medical Science Foundation, USA; Novo Nordisk A/S
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062741	A1	20010830	WO 2001-DK129	20010223 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2001041730	A1	20011115	US 2001-818392	20010327 <--
US 6410743	B2	20020625		

PRIORITY APPLN. INFO.: DK 2000-294 A 20000225 <--
US 2000-185294P P 20000228 <--
WO 2001-DK129 A1 20010223 <--

OTHER SOURCE(S): MARPAT 135:211039
GI



I



II

AB Tetrahydronaphthalene derivs., I (R1 = H, C1-6 alkyl or Ph which is optionally substituted with halogen, OMe, C1-6-alkyl; R2-C-R3 together form a C3-6-cycloalkyl group or a pharmaceutically acceptable salt) were prepared for use in the treatment and/or prevention of type 1 and type 2 diabetes as well as microvascular or macrovascular diseases associated with diabetes. Thus II (R = COC3H5) was prepared in 82% yield and its diHCl in 54% starting from mibefradil diHCl in ethanol and aqueous NaOH via the intermediate II (R = H) which was further reacted with diisopropylethylamine and cyclopropanecarbonyl chloride to yield the free base.

IT **116666-63-8**, Mibefradil dihydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tetrahydronaphthalene derivs. for use in therapy of type 1 and type 2 diabetes)

RN 116666-63-8 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

IT **116666-60-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydronaphthalene derivs. for use in therapy of type 1 and type 2 diabetes)
RN 116666-60-5 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **357400-14-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tetrahydronaphthalene derivs. for use in therapy of type 1 and type 2 diabetes)
RN 357400-14-7 HCAPLUS
CN Cyclopropanecarboxylic acid, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **357400-13-6P 357400-15-8P 357400-16-9P**
357400-17-0P 357400-18-1P 357400-19-2P
357400-21-6P 357400-22-7P 357400-24-9P
357400-25-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydronaphthalene derivs. for use in therapy of type 1 and type 2 diabetes)
RN 357400-13-6 HCAPLUS
CN Cyclopropanecarboxylic acid, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 357400-15-8 HCAPLUS
CN Cyclobutanecarboxylic acid, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357400-16-9 HCAPLUS
CN Cyclopentanecarboxylic acid, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357400-17-0 HCAPLUS
CN Cyclohexanecarboxylic acid, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357400-18-1 HCAPLUS
CN Cyclopropanecarboxylic acid, 1-methyl-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357400-19-2 HCAPLUS
CN Cyclopropanecarboxylic acid, 1-ethyl-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357400-21-6 HCAPLUS
CN Cyclobutanecarboxylic acid, 1-methyl-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357400-22-7 HCAPLUS
CN Cyclobutanecarboxylic acid, 1-ethyl-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357400-24-9 HCAPLUS
CN Cyclopentanecarboxylic acid, 1-methyl-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357400-25-0 HCAPLUS
CN Cyclohexanecarboxylic acid, 1-methyl-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 22 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:636057 HCAPLUS
DOCUMENT NUMBER: 135:211038
TITLE: Preparation of mibefradil analogs for use in the therapy of type 1 and type 2 diabetes
INVENTOR(S): Li, Ming; Hansen, John Bondo; Tagmose, Tina Moller
PATENT ASSIGNEE(S): South Alabama Medical Science Foundation, USA; Novo Nordisk A/S
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001062740	A1	20010830	WO 2001-DK128		20010223 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 2001049447	A1	20011206	US 2001-818398		20010327 <--
PRIORITY APPLN. INFO.:			DK 2000-293	A	20000225 <--
			US 2000-185583P	P	20000228 <--
			WO 2001-DK128	A1	20010223 <--

OTHER SOURCE(S): MARPAT 135:211038
GI



I



II

AB Mibefradil analogs, I (R1, R2 and R3 independently = H, C1-6 alkyl, C3-6 cycloalkyl, C3-6-cycloalkyl-C1-6-alkyl, C1-6-alkyl-C3-6-cycloalkyl or a pharmaceutically acceptable salt) were prepared for use in the treatment and/or prevention of type 1 and type 2 diabetes as well as microvascular or macrovascular diseases associated with diabetes. Thus II (R = COBu) was prepared in 84% yield and the diHCl in 27% yield starting from mibefradil di HCl in ethanol and aqueous NaOH via the intermediate II (R = H) which was further reacted with diisopropylethylamine and valeroyl chloride to yield the free base.

IT **116666-63-8**, Mibefradil dihydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of mibefradil analogs for use in therapy of type 1 and type 2 diabetes)

RN 116666-63-8 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

IT **116666-60-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of mibefradil analogs for use in therapy of type 1 and type 2

diabetes)
RN 116666-60-5 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **357401-28-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of mibefradil analogs for use in therapy of type 1 and type 2 diabetes)
RN 357401-28-6 HCAPLUS
CN Pentanoic acid, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **116644-10-1P 357401-29-7P 357401-30-0P 357401-31-1P 357401-32-2P 357401-33-3P 357401-34-4P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of mibefradil analogs for use in therapy of type 1 and type 2 diabetes)
RN 116644-10-1 HCAPLUS
CN Propanoic acid, 2-methyl-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 357401-29-7 HCAPLUS
CN Pentanoic acid, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 357401-30-0 HCAPLUS
CN Propanoic acid, 2-methyl-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357401-31-1 HCAPLUS
CN Butanoic acid, 3-methyl-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357401-32-2 HCAPLUS
CN Butanoic acid, 2-methyl-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357401-33-3 HCAPLUS
CN Cyclopropaneacetic acid, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357401-34-4 HCAPLUS
CN Cyclopentaneacetic acid, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 23 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:432825 HCAPLUS
DOCUMENT NUMBER: 135:37185
TITLE: Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
INVENTOR(S): Mylari, Banavara Lakshman
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1106210	A2	20010613	EP 2000-310719	20001201 <--
EP 1106210	A3	20031203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002068740	A1	20020606	US 2000-727958	20001201 <--
CA 2327575	AA	20010607	CA 2000-2327575	20001205 <--
JP 2001163805	A2	20010619	JP 2000-369434	20001205 <--
BR 2000005765	A	20010717	BR 2000-5765	20001207 <--
US 2003050301	A1	20030313	US 2002-280388	20021025 <--
PRIORITY APPLN. INFO.:			US 1999-169380P P	19991207 <--
			US 2000-727958 A3	20001201 <--

AB This invention is directed to methods, pharmaceutical compns. and kits comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and an antihypertensive agent, a prodrug thereof or a pharmaceutically acceptable salt of said antihypertensive agent or said prodrug. This invention further relates to methods of using those pharmaceutical compns. for the treatment of diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, myocardial infarction, cataracts and diabetic cardiomyopathy.

IT **116644-53-2**, Mibefradil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing aldose reductase inhibitors and antihypertensive agents for treatment of diabetic complications)

RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-

2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 24 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:394086 HCAPLUS
DOCUMENT NUMBER: 135:523
TITLE: Use of the calcium channel blocker mibefradil for the inhibition of epithelial cell adhesion
INVENTOR(S): Beck, Ria; Guthoff, Rolf; Nebe, Barbara; Rychly, Joachim
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 6 pp.
CODEN: GWXXBX
DOCUMENT TYPE: **Patent**
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19954788	A1	20010531	DE 1999-19954788	19991115 <--

PRIORITY APPLN. INFO.: DE 1999-19954788 19991115 <--

AB The invention discloses a new application/indication of the T-type calcium channel blocker mibefradil dihydrochloride for the inhibition of epithelial cell adhesion in surgical ophthalmol. The invention relates to the problem of after-cataract formation following artificial lens implantation, and suggests a new application for mibefradil for the inhibition of epithelial cells with which it is possible to permanently prevent after-cataract formation. Mibefradil may also be used to inhibit epithelial cell adhesion in vitro.

IT **116644-53-2**, Mibefradil **116666-63-8**, Mibefradil dihydrochloride
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mibefradil for inhibition of epithelial cell adhesion)

RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116666-63-8 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 25 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:338762 HCAPLUS
DOCUMENT NUMBER: 134:362292
TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile
INVENTOR(S): Farr, Spencer
PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA
SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103 <--
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105 <--
US 2000-196571P P 20000411 <--

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.

IT **116644-53-2**, Mibefradil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(methods of determining individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 26 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:152667 HCAPLUS
DOCUMENT NUMBER: 134:188175
TITLE: The use of fluorescein aryl ethers in high throughput cytochrome P450 inhibition assays
INVENTOR(S): Miller, Vaughn P.; Stresser, David; Crespi, Charles L.
PATENT ASSIGNEE(S): Gentest Corporation, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001014361	A1	20010301	WO 2000-US21894		20000810 <--
W: JP					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
EP 1210342	A1	20020605	EP 2000-957373		20000810 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
US 6420131	B1	20020716	US 2000-636332		20000810 <--
JP 2003507466	T2	20030225	JP 2001-518448		20000810 <--
PRIORITY APPLN. INFO.:			US 1999-149762P	P	19990819 <--
			US 1999-150044P	P	19990820 <--
			WO 2000-US21894	W	20000810 <--

OTHER SOURCE(S): MARPAT 134:188175

AB Fluorescent substrates of human cytochrome P 450 enzymes are provided. Also provided are methods for their manufacture and use. These substrates are useful in assessing cytochrome P 450 enzyme activity and in selecting compds. which inhibit cytochrome P 450 enzyme activity and, in particular, for identifying potential adverse drug interactions which are mediated by inhibition of cytochrome P 450 enzyme activity.

IT **116644-53-2**, Mibefradil
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(fluorescein aryl ethers for high throughput cytochrome P 450 inhibition assay)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 27 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:227505 HCAPLUS

DOCUMENT NUMBER: 132:260692

TITLE: Methods and pharmaceutical compositions using 5α-reductase inhibitors combined with calcium channel blockers for treating androgen-related conditions

INVENTOR(S): Waldstreicher, Joanne; Wang, Daniel Z.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2000018402	A1	20000406	WO 1999-US22225		19990924	<--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM						
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
US 6268377	B1	20010731	US 1999-401135		19990922	<--
AU 9962638	A1	20000417	AU 1999-62638		19990924	<--
PRIORITY APPLN. INFO.:			US 1998-102018P	P	19980928	<--
			WO 1999-US22225	W	19990924	<--

OTHER SOURCE(S): MARPAT 132:260692

AB The invention provides for the combined use of 5α-reductase inhibitors together with calcium channel blockers for the treatment of benign prostatic hyperplasia (BPH), prostate cancer, prostatitis, hematuria, and other androgen related disorders, including prostatitis and the prevention of prostate cancer. The invention provides a method of treatment which is useful in the treatment of benign prostatic hyperplasia, prostatitis, and/or the prevention and treatment of prostatic cancer, as well as in the treatment of prostatitis and hematuria. The invention also provides a pharmaceutical composition which is useful in the treatment of benign prostatic hyperplasia, prostatitis, hematuria and/or the prevention and treatment of prostatic cancer, wherein the pharmaceutical composition comprises the combination of a 5α-reductase inhibitor and a calcium channel blocking agent.

IT **116644-53-2**, Mibefradil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined use of 5α-reductase inhibitors and calcium channel blockers for treating androgen-related conditions)

RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 28 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:191261 HCAPLUS
DOCUMENT NUMBER: 132:232751
TITLE: sequence and therapeutic applications for rat pancreatic T-type calcium channel as it relates to diabetes
INVENTOR(S): Li, Ming
PATENT ASSIGNEE(S): South Alabama Medical Science Foundation, USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000015845	A1	20000323	WO 1999-US19675	19990826 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2340586	AA	20000323	CA 1999-2340586	19990826 <--
AU 9960217	A1	20000403	AU 1999-60217	19990826 <--
EP 1108068	A1	20010620	EP 1999-969121	19990826 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002525077	T2	20020813	JP 2000-570372	19990826 <--
US 2003125269	A1	20030703	US 1999-383894	19990826 <--
PRIORITY APPLN. INFO.:			US 1998-98004P P	19980826 <--
			US 1999-117399P P	19990127 <--
			WO 1999-US19675 W	19990826 <--

AB The present invention is directed to isolated nucleic acid mols. encoding pancreatic T-type calcium channels and vectors and host cells comprising such. The invention is further directed to methods and compns. which modulate the expression of pancreatic T-type calcium channels, including antisense. An isolated pancreatic T-type calcium channel protein is provided, as well as antibodies directed to such protein. Pharmaceutical compns. and methods of treatment involving pancreatic T-type calcium channels are also provided. The pharmacol. of Mibefradil action is also discussed and shows that T-type Ca2+ current is more sensitive to mibefradil than the L-type Ca2+ current in pancreatic β-cells. The results also shows that the inhibitory effect of mibefradil on T-type Ca2+ current in pancreatic β-cells results from reversible interaction between the drug and the channel protein. Inhibition of T-type Calcium channels was also shown with a Mibefradil metabolite. Further, it was shown that Streptozotocin induced high basal [Ca2+] inhibits KCL stimulated Ca2+ influx. In addition, it was shown that low voltage-activated Ca2+ current mediates cytokine-induced mouse pancreatic β-cell death. The relationship of this gene to NIDDM (non-insulin-dependent diabetes mellitus) is described. The data suggest that T-type calcium channels are a primary regulator of resting basal [Ca2+] in β-cells. Applications of antisense DNA are revealed which modulate this gene's expression by blocking translation. Expression of a ribozyme is described which results in decreased expression of this rat pancreatic T-type calcium channel. Oligonucleotide probes for genomic or cDNA library screening are also

described along with monoclonal and polyclonal antibodies. Methods for modulation of L-type calcium channels by modifying levels of functional T-type calcium channels is also discussed. Lastly, DNA primers are also mentioned to be used in a PCR reaction for amplification of this gene.

IT **116644-53-2**, Mibefradil
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(sequence and therapeutic applications for rat pancreatic T-type calcium channel as it relates to diabetes)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 29 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:161149 HCAPLUS
DOCUMENT NUMBER: 132:203141
TITLE: Anti-pressor agents and methods for remodeling neuronal and cardiovascular pathways for the long term management of sexual dysfunction
INVENTOR(S): Adams, Michael A.; Heaton, Jeremy P. W.
PATENT ASSIGNEE(S): Queen's University At Kingston, Can.
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012110	A2	20000309	WO 1999-CA787	19990825 <--
WO 2000012110	A3	20000803		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2340206	AA	20000309	CA 1999-2340206	19990825 <--
AU 9954034	A1	20000321	AU 1999-54034	19990825 <--

EP 1235563 A2 20020904 EP 1999-939874 19990825 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
PRIORITY APPLN. INFO.: US 1998-98178P P 19980826 <--
WO 1999-CA787 W 19990825 <--

AB The invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compds. selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, α1-adrenergic receptor antagonists, β-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors. The anti-pressor agent may be co-administered with a diuretic compound, and is administered either chronically at low dose, or for short periods of time at doses higher than are typically used for the treatment of hypertension. In certain embodiments of the method of the invention, the anti-pressor agent is co-administered with a diuretic agent and/or prostaglandin-E1.

IT **116644-53-2**, Mibefradil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-pressor agents and methods for remodeling neuronal and cardiovascular pathways for long term management of sexual dysfunction)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 30 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:83199 HCAPLUS
DOCUMENT NUMBER: 132:113122
TITLE: Water-soluble tablet containing sildenafil
INVENTOR(S): Struengmann, Thomas
PATENT ASSIGNEE(S): Hexal A.-G., Germany
SOURCE: Ger. Offen., 4 pp.
CODEN: GWXXBX
DOCUMENT TYPE: **Patent**
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19834507	A1	20000203	DE 1998-19834507	19980731 <--
WO 2000007596	A1	20000217	WO 1999-EP5464	19990730 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9954156	A1	20000228	AU 1999-54156	19990730 <--
PRIORITY APPLN. INFO.:			DE 1998-19834507 A	19980731 <--
			WO 1999-EP5464 W	19990730 <--

AB Sildenafil (Viagra) or 1 of its pharmaceutically acceptable salts is administered in a water-soluble tablet formulation to hasten its onset of action in inducing an erection. The composition may addnl. contain a cytochrome P 450 inhibitor to decrease the rate of sildenafil metabolism and increase its plasma concentration The composition is resorbed well, and patient compliance is good.

IT **116644-53-2**, Mibefradil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-soluble tablet containing sildenafil)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 31 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	2000:83198 HCAPLUS
DOCUMENT NUMBER:	132:113121
TITLE:	Transmucosal therapeutic system for the use of sildenafil
INVENTOR(S):	Struengmann, Thomas
PATENT ASSIGNEE(S):	Hexal A.-G., Germany
SOURCE:	Ger. Offen., 4 pp. CODEN: GWXXBX
DOCUMENT TYPE:	**Patent**
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

DE 19834506	A1	20000203	DE 1998-19834506	19980731 <--
WO 2000007597	A1	20000217	WO 1999-EP5465	19990730 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9952898	A1	20000228	AU 1999-52898	19990730 <--
PRIORITY APPLN. INFO.:			DE 1998-19834506 A	19980731 <--
			WO 1999-EP5465 W	19990730 <--

AB Sildenafil (Viagra) or 1 of its pharmaceutically acceptable salts is administered transmucosally as a spray, cream, gel, powder, or drops to hasten its onset of action in inducing an erection. This mode of administration improves the drug bioavailability and thereby decreases the dosage required and the risk of side effects. The composition may addnl. contain a cytochrome P 450 inhibitor to decrease the rate of sildenafil metabolism and increase its plasma concentration The composition does not irritate the mucosa.

IT **116644-53-2**, Mibefradil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transmucosal therapeutic system for use of sildenafil)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 32 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	2000:83197 HCAPLUS
DOCUMENT NUMBER:	132:113120
TITLE:	Transdermal therapeutic system for the use of sildenafil
INVENTOR(S):	Struengmann, Thomas; Spaeth, Wolfgang
PATENT ASSIGNEE(S):	Hexal A.-G., Germany
SOURCE:	Ger. Offen., 4 pp. CODEN: GWXXBX
DOCUMENT TYPE:	**Patent**
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19834505	A1	20000203	DE 1998-19834505	19980731 <--

PRIORITY APPLN. INFO.: DE 1998-19834505 19980731 <--

AB Sildenafil (Viagra) or 1 of its pharmaceutically acceptable salts is used as a topical cream, lotion, or transdermal plaster to hasten its onset of action in inducing an erection. This mode of administration improves the drug bioavailability and bypasses the 1st-pass effect in metabolism of the drug by the liver, and thereby decreases the dosage required and the risk of side effects. The composition may addnl. contain a cytochrome P 450 inhibitor to decrease the rate of sildenafil metabolism and increase its plasma concentration The topical or transdermal dosage form can be removed after use to avoid the occurrence of priapism.

IT **116644-53-2**, Mibefradil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal therapeutic system for use of sildenafil)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 33 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:53366 HCAPLUS
DOCUMENT NUMBER: 132:88204
TITLE: Method of treatment and pharmaceutical composition using valsartan-calcium channel blocker combination
INVENTOR(S): De Gasparo, Marc; Webb, Randy Lee
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002543	A2	20000120	WO 1999-EP4842	19990709 <--
WO 2000002543	A3	20000629		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,

MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2336822	AA	20000120	CA 1999-2336822	19990709 <--
AU 9950349	A1	20000201	AU 1999-50349	19990709 <--
AU 753486	B2	20021017		
BR 9912021	A	20010403	BR 1999-12021	19990709 <--
EP 1096932	A2	20010509	EP 1999-934647	19990709 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100062	T2	20010621	TR 2001-200100062	19990709 <--
JP 2002520274	T2	20020709	JP 2000-558803	19990709 <--
NZ 509260	A	20030926	NZ 1999-509260	19990709 <--
NO 2001000113	A	20010309	NO 2001-113	20010108 <--
ZA 2001000232	A	20020409	ZA 2001-232	20010109 <--
PRIORITY APPLN. INFO.:			US 1998-113893 A	19980710 <--
			WO 1999-EP4842 W	19990709 <--

AB A method is provided for the treatment or prevention of a condition or disease selected from hypertension, (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, myocardial infarction and its sequelae supraventricular and ventricular arrhythmias, atrial fibrillation or atrial flutter, atherosclerosis, angina (whether stable or unstable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, hypertension in patients with NIDDM, secondary aldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), and stroke, comprising administering a therapeutically effective amount of combination of (i) the AT1-antagonist valsartan or a pharmaceutically acceptable salt thereof and (ii) a calcium channel blocker or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to a mammal in need of such treatment. A corresponding pharmaceutical combination composition is also provided.

IT **116644-53-2**, Mibefradil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(valsartan-calcium channel blocker pharmaceutical combination)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 34 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:819361 HCAPLUS
DOCUMENT NUMBER: 132:44979
TITLE: Nitrate salts of antihypertensive medicines
INVENTOR(S): Del, Soldato Piero
PATENT ASSIGNEE(S): Nicox S. A., Fr.
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9967231	A1	19991229	WO 1999-EP4138	19990615 <--
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, IL, IN, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1301759	B1	20000707	IT 1998-MI1408	19980619 <--
CA 2335356	AA	19991229	CA 1999-2335356	19990615 <--
AU 9945139	A1	20000110	AU 1999-45139	19990615 <--
AU 770387	B2	20040219		
EP 1087953	A1	20010404	EP 1999-927990	19990615 <--
EP 1087953	B1	20041117		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, SI, LT, FI, RO				
BR 9911305	A	20011023	BR 1999-11305	19990615 <--
JP 2002518492	T2	20020625	JP 2000-555885	19990615 <--
RU 2235097	C2	20040827	RU 2000-131690	19990615 <--
ZA 2000006136	A	20020130	ZA 2000-6136	20001030 <--
US 6645965	B1	20031111	US 2000-719164	20001212 <--
US 2004147575	A1	20040729	US 2003-671746	20030929 <--

PRIORITY APPLN. INFO.:	IT 1998-MI1408	A	19980619 <--
	WO 1999-EP4138	W	19990615 <--
	US 2000-719164	A3	20001212 <--

OTHER SOURCE(S): MARPAT 132:44979

AB Nitric acid salts of drugs have antihypertensive activity. Some example salts prepared and showing antihypertensive activity were: timolol, propranolol, sildenafil, valsartan, hydralazine, nicardipine, verapamil, and amiloride nitrate salts.

IT **252951-80-7**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrate salts of antihypertensive medicines)

RN 252951-80-7 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, nitrate (9CI) (CA INDEX NAME)

CM 1

CRN 116644-53-2
CMF C29 H38 F N3 O3

Absolute stereochemistry.



CM 2

CRN 7697-37-2
CMF H N O3



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 35 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:795648 HCAPLUS
DOCUMENT NUMBER: 132:35723
TITLE: Multibinding, multimeric ligands comprising calcium channel blockers
INVENTOR(S): Ji, Yu-Hau; Natarajan, Maya; Griffin, John H.
PATENT ASSIGNEE(S): Advanced Medicine, Inc., USA
SOURCE: PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9963992	A1	19991216	WO 1999-US12672	19990607 <--
WO 9963992	C2	20020822		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,

MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2318806 AA 19991216 CA 1999-2318806 19990607 <--
CA 2318901 AA 19991216 CA 1999-2318901 19990607 <--
CA 2319142 AA 19991216 CA 1999-2319142 19990607 <--
CA 2319153 AA 19991216 CA 1999-2319153 19990607 <--
WO 9963984 A1 19991216 WO 1999-US11801 19990607 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
WO 9963932 A2 19991216 WO 1999-US12724 19990607 <--
WO 9963932 A3 20000203
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
WO 9964045 A1 19991216 WO 1999-US12754 19990607 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9945493 A1 19991230 AU 1999-45493 19990607 <--
AU 9945511 A1 19991230 AU 1999-45511 19990607 <--
AU 9946726 A 19991230 AU 1999-46726 19990607 <--
EP 1085863 A1 20010328 EP 1999-928427 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085879 A2 20010328 EP 1999-928442 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085890 A1 20010328 EP 1999-930122 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1089749 A1 20010411 EP 1999-928447 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 2002517437 T2 20020618 JP 2000-553053 19990607 <--
JP 2002517440 T2 20020618 JP 2000-553061 19990607 <--
SG 80038 A1 20010417 SG 1999-2716 19990608 <--
ZA 2000004562 A 20011130 ZA 2000-4562 20000831 <--
ZA 2000004563 A 20011130 ZA 2000-4563 20000831 <--
ZA 2000004564 A 20011130 ZA 2000-4564 20000831 <--

US 2003044845	A1	20030306	US 2002-75017		20020213 <--
PRIORITY APPLN. INFO.:			US 1998-88465P	P	19980608 <--
			US 1998-93068P	P	19980716 <--
			US 1998-103866P	P	19981012 <--
			US 1999-327096	B1	19990607 <--
			WO 1999-US11801	W	19990607 <--
			WO 1999-US12672	W	19990607 <--
			WO 1999-US12724	W	19990607 <--
			WO 1999-US12754	W	19990607 <--
			US 2000-499176	B1	20000207 <--

AB Novel multibinding compds., which are multimeric ligands, are disclosed. The compds. comprise 2-10 ligands, covalently connected via 1-20 linkers, with each ligand being capable of binding to a ligand-binding site in a Ca++ channel. The ligands may be selected from representative calcium channel blockers, including verapamil, diltiazem, benziazem, clentiazem, nicardipine, nifedipine, nilvadipine, nitrendipine, nimodipine, isradipine, lacidipine, amlodipine, nisoldipine, felodipine, bepridil, mibefradil, SQ 32910, and SQ 32428. The ligands may be identified via a combinatorial library based upon varying ligands and/or linkers. Several prophetic examples are given, using amlodipine, verapamil, diltiazem, and other ligand components.

IT **116644-53-2DP**, Mibefradil, dimeric and multimeric derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of multibinding multimeric ligands comprising calcium channel blockers)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 36 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1999:377851 HCAPLUS
DOCUMENT NUMBER:	131:29119
TITLE:	Low-voltage activated calcium channel proteins and cDNAs encoding them and the development of calcium channel blockers
INVENTOR(S):	Williams, Mark; Stauderman, Kenneth; Harpold, Michael; Hans, Michael; Urrutia, Arturo; Washburn, Mark S.
PATENT ASSIGNEE(S):	Sibia Neurosciences, Inc., USA
SOURCE:	PCT Int. Appl., 171 pp. CODEN: PIXXD2
DOCUMENT TYPE:	**Patent**
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9928342	A2	19990610	WO 1998-US25671	19981203 <--
WO 9928342	A3	19990826		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6528630	B1	20030304	US 1997-984709	19971203 <--
CA 2312195	AA	19990610	CA 1998-2312195	19981203 <--
AU 9918026	A1	19990616	AU 1999-18026	19981203 <--
AU 760309	B2	20030515		
EP 1042468	A2	20001011	EP 1998-962884	19981203 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2001525161	T2	20011211	JP 2000-523233	19981203 <--
PRIORITY APPLN. INFO.:			US 1997-984709 A1	19971203 <--
			US 1998-188932 A	19981110 <--
			WO 1998-US25671 W	19981203 <--

AB CDNAs for alternative splicing forms of the α1 subunit of the T-type or low-voltage activated calcium channel are cloned and characterized. The cDNAs may be used in the development of systems for screening for effectors of the calcium channel for therapeutic use. Candidate clones were first generated by PCR using degenerate primers targeted against sequences encoding conserved regions of the protein. A series of overlapping cDNAs encoding two α1H subtypes were obtained and full-length cDNAs constructed. The electrophysiol. and pharmacol. of the channels was studied in Xenopus oocytes.

IT **116644-53-2**, Mibefradil
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(as calcium channel antagonist; low-voltage activated calcium channel proteins and cDNAs encoding them and development of calcium channel blockers)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 37 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:184130 HCAPLUS
DOCUMENT NUMBER: 130:205139
TITLE: Combination therapy comprising atorvastatin and an antihypertensive agent
INVENTOR(S): Scott, Robert Andrew Donald
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9911260	A1	19990311	WO 1998-IB1230		19980811 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9884589	A1	19990322	AU 1998-84589		19980811 <--
AU 740424	B2	20011101			
EP 1009400	A1	20000621	EP 1998-935250		19980811 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO					
TR 200000563	T2	20000721	TR 2000-200000563		19980811 <--
BR 9811556	A	20000822	BR 1998-11556		19980811 <--
JP 2001514223	T2	20010911	JP 2000-508363		19980811 <--
NZ 502280	A	20021126	NZ 1998-502280		19980811 <--
CN 1473566	A	20040211	CN 2003-2003143092		19980811 <--
CN 1473567	A	20040211	CN 2003-2003143093		19980811 <--
AP 1191	A	20030719	AP 1998-1332		19980827 <--
W: BW, GM, KE, MW, UG, ZM, ZW					
ZA 9807839	A	20000228	ZA 1998-7839		19980828 <--
NO 2000000996	A	20000427	NO 2000-996		20000228 <--
US 2002099046	A1	20020725	US 2001-45329		20011023 <--
US 2003199492	A1	20031023	US 2003-442285		20030519 <--
PRIORITY APPLN. INFO.:			US 1997-57276P	P	19970829 <--
			WO 1998-IB1230	W	19980811 <--
			US 2000-513887	B1	20000225 <--
			US 2001-45329	B1	20011023 <--

AB This invention relates to pharmaceutical combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.

IT **116644-53-2**, Mibefradil

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy comprising atorvastatin and antihypertensive agent)

RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 38 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:104627 HCAPLUS
DOCUMENT NUMBER: 130:205140
TITLE: Potential-dependent, T-type calcium channel inhibitors for treatment or prevention of pollakiuria or urinary incontinence
INVENTOR(S): Narita, Kazuhisa; Koga, Ichiro; Okada, Atsushi
PATENT ASSIGNEE(S): Nippon Kayaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11035483	A2	19990209	JP 1998-128463	19980512 <--
PRIORITY APPLN. INFO.:			JP 1997-144503	19970520 <--

AB Potential-dependent, T-type calcium channel inhibitors e.g. [1S, 2S]-2-[2-[[3-[2-benzimidazolyl]propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthylmethoxyacetate and 7-[4-[4,4'-difluorobenzohydryl]piperadino-1-methyl]-2-[[2-hydroxyethyl]amino]-4-isopropyl-2,4,6-cycloheptatrien-1-one for treatment or prevention of pollakiuria or urinary incontinence are claimed.

IT **220873-01-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potential-dependent, T-type calcium channel inhibitors for treatment or prevention of pollakiuria or urinary incontinence)

RN 220873-01-8 HCAPLUS
CN Ethanone, 1-[(1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 39 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:721683 HCAPLUS
DOCUMENT NUMBER: 129:330729
TITLE: Preparation of mibefradil I.
INVENTOR(S): Fleming, Michael Paul; Harrington, Peter John
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9849149	A1	19981105	WO 1998-EP2416		19980423 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9876477	A1	19981124	AU 1998-76477		19980423 <--
PRIORITY APPLN. INFO.:			US 1997-45151P	P	19970430 <--
			WO 1998-EP2416	W	19980423 <--

OTHER SOURCE(S): CASREACT 129:330729
AB 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate was prepared by reducing N-[3-(1H-benzimidazol-2-yl)propyl]-2-(6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylacetamide to give 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol and contacting the latter with MeOCH2CO2H or an activated derivative thereof.
IT **116644-53-2P**, Mibefradil **116666-63-8P**, Mibefradil dihydrochloride **213272-70-9P**, 2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate **213272-71-0P**, 2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate dihydrochloride

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of mibefradil)

RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116666-63-8 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 213272-70-9 HCAPLUS
CN Acetic acid, methoxy-, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 213272-71-0 HCAPLUS
CN Acetic acid, methoxy-, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-

2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **213272-66-3**, N-[3-(1H-Benzimidazol-2-yl)propyl]-2-(6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylacetamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of mibefradil)

RN 213272-66-3 HCAPLUS

CN 2-Naphthaleneacetamide, N-[3-(1H-benzimidazol-2-yl)propyl]-6-fluoro-1,2,3,4-tetrahydro-2-hydroxy-N-methyl-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT **116666-60-5P**, (1S,2S)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol **212967-75-4P**, (1S,2S)-N-[3-(1H-Benzimidazol-2-yl)propyl]-2-(6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylacetamide **213272-63-0P**, (1S,2S)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol dioxalate **213272-69-6P**, 2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of mibefradil)

RN 116666-60-5 HCAPLUS

CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212967-75-4 HCAPLUS
CN 2-Naphthaleneacetamide, N-[3-(1H-benzimidazol-2-yl)propyl]-6-fluoro-1,2,3,4-tetrahydro-2-hydroxy-N-methyl-1-(1-methylethyl)-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 213272-63-0 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-, (1S,2S)-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 116666-60-5
CMF C26 H34 F N3 O

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 213272-69-6 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-

fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 40 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:721682 HCAPLUS
DOCUMENT NUMBER: 129:343493
TITLE: Preparation of mibefradil II.
INVENTOR(S): Harrington, Peter John; Wong, Jim-wah
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9849148	A1	19981105	WO 1998-EP2415		19980423 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9879092	A1	19981124	AU 1998-79092		19980423 <--
PRIORITY APPLN. INFO.:			US 1997-46795P	P	19970430 <--
			WO 1998-EP2415	W	19980423 <--

OTHER SOURCE(S): CASREACT 129:343493

AB A process for preparation of 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate via contacting (6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4- tetrahydronaphthalen-2-yl)acetic acid or an activated derivative thereof with [3-(1H- benzimidazol-2-yl)propyl]methylamine to form N-[3-(1H-benzimidazol-2-yl)propyl]-2-(6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylacetamide is claimed.

IT **116644-53-2P**, Mibefradil **116666-63-8P**, Mibefradil dihydrochloride **213272-70-9P**, 2-[2-{[3-(1H-Benzimidazol-2-yl) propyl]methyl-amino}ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of mibefradil)

RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116666-63-8 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 213272-70-9 HCAPLUS
CN Acetic acid, methoxy-, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)



IT **116666-60-5P**, (1S,2S)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol **212967-75-4P 213272-63-0P**

213272-66-3P, N-[3-(1H)-Benzimidazol-2-yl)propyl]-2-(6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylacetamide
213272-69-6P, 2-[2-{[3-(1H-Benzimidazol-2-yl)propyl]methylamino}ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of mibefradil)

RN 116666-60-5 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212967-75-4 HCAPLUS
CN 2-Naphthaleneacetamide, N-[3-(1H-benzimidazol-2-yl)propyl]-6-fluoro-1,2,3,4-tetrahydro-2-hydroxy-N-methyl-1-(1-methylethyl)-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 213272-63-0 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-, (1S,2S)-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 116666-60-5
CMF C26 H34 F N3 O

Absolute stereochemistry.



Searched by P. Ruppel

CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 213272-66-3 HCAPLUS
CN 2-Naphthaleneacetamide, N-[3-(1H-benzimidazol-2-yl)propyl]-6-fluoro-1,2,3,4-tetrahydro-2-hydroxy-N-methyl-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 213272-69-6 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 41 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:721681 HCAPLUS
DOCUMENT NUMBER: 129:343492
TITLE: Preparation of mibefradil III.
INVENTOR(S): Harrington, Peter John; Wong, Jim-wah

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9849147	A1	19981105	WO 1998-EP2406	19980423 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9876473	A1	19981124	AU 1998-76473	19980423 <--
PRIORITY APPLN. INFO.:			US 1997-45150P P	19970430 <--
			WO 1998-EP2406 W	19980423 <--

OTHER SOURCE(S): CASREACT 129:343492

AB 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate was prepared by contacting [3-(1H-benzimidazol-2-yl)propyl]methylamine with (6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)acetonitrile in the presence of H2 and a hydrogenation catalyst, followed by contacting the resulting 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol with MeOCH2CO2H or an activated derivative thereof.

IT **116644-53-2P**, (1S,2S)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate **116666-63-8P**, Mibefradil dihydrochloride **213272-70-9P**, 2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of mibefradil)

RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116666-63-8 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-

2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 213272-70-9 HCAPLUS
CN Acetic acid, methoxy-, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester. (9CI) (CA INDEX NAME)



IT **116666-60-5P**, (1S,2S)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol **213272-63-0P 213272-69-6P**, 2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of mibefradil)

RN 116666-60-5 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 213272-63-0 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-

fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-, (1S,2S)-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 116666-60-5
CMF C26 H34 F N3 O

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 213272-69-6 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 42 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:618399 HCAPLUS
DOCUMENT NUMBER: 129:245150
TITLE: Improved preparation of mibefradil via an acetonitrile anion
INVENTOR(S): Wong, Jim-wah; Harrington, Peter J.
PATENT ASSIGNEE(S): Roche Colorado Corp., USA

SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5811557	A	19980922	US 1998-60401	19980414 <--
PRIORITY APPLN. INFO.:			US 1998-60401	19980414 <--

OTHER SOURCE(S): CASREACT 129:245150
GI



I



II



III

AB A method of preparing 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate (I) comprises contacting 6-fluoro-1-isopropyl-3,4-dihydro-1H-naphthalen-2-one with the anion of acetonitrile in an aprotic polar solvent, contacting the thus-formed (6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)acetonitrile (II) with [3-(1H-benzimidazol-2-yl)propyl]methylamine(III) in the presence of hydrogen and a hydrogenation catalyst, and finally esterifying the obtained 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol with methoxyacetic acid or an activated derivative of it. The invention is particularly applicable to the preparation of the antihypertensive mibefradil, namely (1S,2S)-I, and its di-HCl salt. The intermediate nitrile II is a new compound

IT **116644-53-2P**, Mibefradil **116666-63-8P**, Mibefradil dihydrochloride **213272-70-9P**, 2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(improved preparation of mibefradil via an acetonitrile anion)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116666-63-8 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 213272-70-9 HCAPLUS
CN Acetic acid, methoxy-, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)



IT **116666-60-5P**, (1S,2S)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol **213272-63-0P**, (1S,2S)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol dioxalate **213272-69-6P**, 2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; improved preparation of mibefradil via an acetonitrile anion)

RN 116666-60-5 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 213272-63-0 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-, (1S,2S)-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 116666-60-5
CMF C26 H34 F N3 O

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 213272-69-6 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 43 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:618398 HCAPLUS
DOCUMENT NUMBER: 129:245149
TITLE: Improved preparation of mibefradil via a naphthalenylacetic acid
INVENTOR(S): Harrington, Peter J.; Wong, Jim-wah
PATENT ASSIGNEE(S): Roche Colorado Corp., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5811556	A	19980922	US 1998-60168	19980414 <--
PRIORITY APPLN. INFO.:			US 1998-60168	19980414 <--

OTHER SOURCE(S): CASREACT 129:245149
GI



I



II



III

AB A method of preparing 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate (I) comprises contacting (6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acid (II) or an activated derivative with [3-(1H-benzimidazol-2-yl)propyl]methylamine(III), reducing the formed amide function to a tertiary amine, and esterifying the obtained hydroxy amine with methoxyacetic acid or an activated derivative of it. The invention is particularly applicable to the preparation of the antihypertensive mibefradil, i.e., (1S,2S)-I, and its di-HCl salt. The intermediate amide, namely N-[3-(1H-benzimidazol-2-yl)propyl]-2-(6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylacetamide, is a new compound

IT **116666-60-5P**, (1S,2S)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol **212967-75-4P**, (1S,2S)-N-[3-(1H-Benzimidazol-2-yl)propyl]-2-(6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylacetamide **213272-63-0P**, (1S,2S)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol dioxalate **213272-66-3P**, N-[3-(1H-Benzimidazol-2-yl)propyl]-2-(6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylacetamide **213272-69-6P**, 2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of mibefradil via a naphthalenylacetic acid)

RN 116666-60-5 HCAPLUS

CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212967-75-4 HCAPLUS

CN 2-Naphthaleneacetamide, N-[3-(1H-benzimidazol-2-yl)propyl]-6-fluoro-1,2,3,4-tetrahydro-2-hydroxy-N-methyl-1-(1-methylethyl)-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 213272-63-0 HCAPLUS

CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-, (1S,2S)-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 116666-60-5
CMF C26 H34 F N3 O

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 213272-66-3 HCAPLUS
CN 2-Naphthaleneacetamide, N-[3-(1H-benzimidazol-2-yl)propyl]-6-fluoro-1,2,3,4-tetrahydro-2-hydroxy-N-methyl-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 213272-69-6 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT **116644-53-2P**, Mibefradil **116666-63-8P**, Mibefradil dihydrochloride **213272-70-9P**, 2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate **213272-71-0P**, 2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate dihydrochloride
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of mibefradil via a naphthalenylacetic acid)

RN 116644-53-2 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116666-63-8 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 213272-70-9 HCAPLUS
CN Acetic acid, methoxy-, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 213272-71-0 HCAPLUS
CN Acetic acid, methoxy-, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 44 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:604714 HCAPLUS
DOCUMENT NUMBER: 129:230726
TITLE: Preparation of mibefradil via an acetamide anion
INVENTOR(S): Harrington, Peter J.; Fleming, Michael P.
PATENT ASSIGNEE(S): Roche Colorado Corporation, USA
SOURCE: U.S., 7 pp.

CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5808088	A	19980915	US 1998-60151	19980414 <--
US 5892055	A	19990406	US 1998-106058	19980626 <--

PRIORITY APPLN. INFO.: US 1998-60151 19980414 <--
OTHER SOURCE(S): CASREACT 129:230726

AB A method of preparing 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate comprises contacting 6-fluoro-1-isopropyl-3,4-dihydro-1H-naphthalen-2-one with the dianion of N-[3-(1H-benzimidazol-2-yl)propyl]-N-methylacetamide to form N-[3-(1H-benzimidazol-2-yl)propyl]-2-(6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylacetamide, reducing this to 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol, and treating the 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol with methoxyacetic acid or an activated derivative of methoxyacetic acid. The invention is particularly applicable to the preparation of mibefradil, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro- 1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate, and its dihydrochloride salt. N-[3-(1H-Benzimidazol-2-yl)propyl]-N-methylacetamide, and the acetic acid solvate of 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol dioxalate, are new.

IT **116666-60-5P 212967-75-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of mibefradil via an acetamide anion)

RN 116666-60-5 HCAPLUS
CN 2-Naphthalenol, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212967-75-4 HCAPLUS
CN 2-Naphthaleneacetamide, N-[3-(1H-benzimidazol-2-yl)propyl]-6-fluoro-1,2,3,4-tetrahydro-2-hydroxy-N-methyl-1-(1-methylethyl)-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **116644-53-2P 116666-63-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of mibefradil via an acetamide anion)
RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116666-63-8 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 45 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:555763 HCAPLUS
DOCUMENT NUMBER: 127:161594
TITLE: Dehydrative process for the preparation of aromatic alpha,beta-unsaturated carboxylic acids

INVENTOR(S): Foricher, Joseph; Schmid, Rudolf
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: **Patent**
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 787711	A2	19970806	EP 1997-100843	19970121 <--
EP 787711	A3	19980107		
EP 787711	B1	20000426		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5910606	A	19990608	US 1997-780952	19970110 <--
JP 09208516	A2	19970812	JP 1997-5425	19970116 <--
CA 2195617	AA	19970801	CA 1997-2195617	19970121 <--
AT 192135	E	20000515	AT 1997-100843	19970121 <--
ES 2146041	T3	20000716	ES 1997-100843	19970121 <--
PT 787711	T	20000929	PT 1997-100843	19970121 <--
CN 1162589	A	19971022	CN 1997-102090	19970128 <--
CN 1069629	B	20010815		
BR 9700814	A	19980707	BR 1997-814	19970130 <--
GR 3033816	T3	20001031	GR 2000-401516	20000629 <--

PRIORITY APPLN. INFO.: CH 1996-247 A 19960131 <--
OTHER SOURCE(S): CASREACT 127:161594; MARPAT 127:161594

AB The title compds. R12C:C(A)CO2H [A = (un)substituted aryl; R1 = C1-5 alkyl] are prepared in high yield and selectivity by the dehydration of hydroxycarboxylic acids HO(R1)2CCH(A)CO2H in the presence of a strong acid at 0-40°. Thus, 2-(4-fluorophenyl)-3-hydroxy-3-methylbutyric acid was dehydrated with concentrated H2SO4 at 20°, producing 99.8%-pure 2-(4-fluorophenyl)-3-methylcrotonic acid (m.p. 124-126°) in 95.7% yield.

IT **116644-53-2DP**, Mibefradil, intermediates
RL: SPN (Synthetic preparation); PREP (Preparation)
(dehydrative process for the preparation of aromatic alpha,beta-unsatd. carboxylic acids)

RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 46 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:144163 HCAPLUS
DOCUMENT NUMBER: 120:144163
TITLE: Topical ophthalmic compositions comprising a

combination of calcium antagonists with known antiglaucoma agents
INVENTOR(S): Desantis, Louis, Jr.
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 20 PP.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9323082	A1	19931125	WO 1993-US4505		19930512 <--
W: AU, CA, JP					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9342467	A1	19931213	AU 1993-42467		19930512 <--
EP 639986	A1	19950301	EP 1993-911276		19930512 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
JP 07508030	T2	19950907	JP 1993-503718		19930512 <--
PRIORITY APPLN. INFO.:			US 1992-882328	A	19920513 <--
			WO 1993-US4505	A	19930512 <--

AB Calcium antagonists and compds. which lower intraocular pressure are combined in ophthalmic compns. to treat glaucoma. The calcium antagonists prevent or reduce the loss of visual field, while the intraocular pressure-lowering compds. maintain the intraocular pressure at normal levels.

IT **116666-63-8**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium antagonist, ophthalmic compns. containing intraocular pressure-lowering agents and, for glaucoma treatment)

RN 116666-63-8 HCAPLUS

CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L26 ANSWER 47 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:219851 HCAPLUS
DOCUMENT NUMBER: 118:219851
TITLE: Antihypertensive combination pharmaceuticals
INVENTOR(S): Clozel, Jean Paul; Mueller, Rita; Osterrieder, Wolfgang

PATENT ASSIGNEE(S): Hoffmann-La Roche, F., A.-G., Switz.
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: **Patent**
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 524512	A2	19930127	EP 1992-111847	19920711	<--
EP 524512	A3	19930901			
EP 524512	B1	20040303			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE					
AT 260661	E	20040315	AT 1992-111847	19920711	<--
PT 524512	T	20040730	PT 1992-111847	19920711	<--
ES 2215160	T3	20041001	ES 1992-111847	19920711	<--
CA 2074039	AA	19930124	CA 1992-2074039	19920716	<--
CA 2074039	C	20041102			
ZA 9205322	A	19930331	ZA 1992-5322	19920716	<--
IL 102541	A1	19951208	IL 1992-102541	19920717	<--
AU 9220416	A1	19930128	AU 1992-20416	19920720	<--
AU 656207	B2	19950127			
HU 62792	A2	19930628	HU 1992-2367	19920720	<--
HU 214029	B	19971229			
RU 2084225	C1	19970720	RU 1992-5052378	19920720	<--
RO 110905	B3	19960530	RO 1992-990	19920721	<--
CZ 281691	B6	19961211	CZ 1992-2270	19920721	<--
SK 278918	B6	19980408	SK 1992-2270	19920721	<--
NO 9202903	A	19930125	NO 1992-2903	19920722	<--
CN 1068737	A	19930210	CN 1992-108668	19920722	<--
CN 1040505	B	19981104			
BR 9202830	A	19930323	BR 1992-2830	19920723	<--
JP 05194217	A2	19930803	JP 1992-216629	19920723	<--
JP 06080009	B4	19941012			
HR 930953	B1	20030630	HR 1993-930953	19930607	<--
US 5620975	A	19970415	US 1994-333171	19941102	<--
PRIORITY APPLN. INFO.:			CH 1991-2191 A	19910723	<--
			US 1992-909357 B1	19920706	<--
			US 1994-210095 B1	19940317	<--

OTHER SOURCE(S): MARPAT 118:219851
GI



I II



III

AB Antihypertensive pharmaceuticals consist of a mixture of tetrahydronaphthalene derivative (I, R1 = e.g., halo, R2 = lower alkoxy or alkylcarbonyloxy, X = C2-8 alkylene and A = N-alkyl substituted benzimidazolyl) and a pyridazodiazepine (II, R1 = C1-6 aralkyl R2, R3 = H or C1-6 alkyl, R4 and R5 = H or R4R5 = O). By using the combination, individual drug doses can be reduced, undesired side effects are reduced, and both compds. have a similar long biol. half life of 10-12 h during treatment in human. Thus, a tablet core composition was prepared starting from III 29.07, clizapril 1.25, anhydrous lactose 70.18, corn starch 30.00, poly(vinylpyrrolidone) 5.00, talc 5.00, and Na stearyl fumarate 1.50 mg. A coating composition for tablets contained hydroxypropyl Me cellulose 4.00, polyethylene glycol 6000 1.00, TiO2 1.60, and talc 1.40 mg. The tablet core was coated with the coating composition The effectiveness of the combination drugs in decreasing hypertension was demonstrated.

IT **147455-39-8 147471-62-3**
RL: BIOL (Biological study)
(antihypertensive combination pharmaceuticals containing pyridazodiazepine derivative and)

RN 147455-39-8 HCAPLUS
CN Acetic acid, [[2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl]methoxy]-, methyl ester, (1S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 147471-62-3 HCAPLUS
CN Acetic acid, [[2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl]methoxy]-, dihydrochloride, (1S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L26 ANSWER 48 OF 48 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1988:549535 HCAPLUS
DOCUMENT NUMBER: 109:149535
TITLE: Preparation of [[(heterocyclylalkyl)amino]ethyl]tetrahydronaphthalenes as cardiovascular agents
INVENTOR(S): Branca, Quirico; Jaunin, Roland; Maerki, Hans Peter; Marti, Fraenzi; Ramuz, Henri
PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.
SOURCE: Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DOCUMENT TYPE: **Patent**
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 268148	A1	19880525	EP 1987-116251	19871104 <--
EP 268148	B1	19911211		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8705599	A	19880515	DK 1987-5599	19871026 <--
DK 171349	B1	19960916		
CA 1319144	A1	19930615	CA 1987-550190	19871026 <--
CS 264350	B2	19890712	CS 1987-7874	19871103 <--
AT 70267	E	19911215	AT 1987-116251	19871104 <--
ES 2040234	T3	19931016	ES 1987-116251	19871104 <--
ZA 8708362	A	19880727	ZA 1987-8362	19871106 <--
AU 8780909	A1	19880519	AU 1987-80909	19871109 <--
AU 600769	B2	19900823		
IL 84407	A1	19910916	IL 1987-84407	19871109 <--
JP 63139171	A2	19880610	JP 1987-282287	19871110 <--
JP 2504490	B2	19960605		
US 4808605	A	19890228	US 1987-119114	19871110 <--
HU 60251	A2	19920828	HU 1987-5011	19871111 <--
HU 215915	B	19990329		
FI 8705024	A	19880515	FI 1987-5024	19871113 <--
FI 94414	B	19950531		
FI 94414	C	19950911		
NO 8704757	A	19880516	NO 1987-4757	19871113 <--
NO 172237	B	19930315		
NO 172237	C	19930623		

CN 87107875	A	19880525	CN 1987-107875		19871113 <--
CN 1028991	B	19950621			
PRIORITY APPLN. INFO.:			CH 1986-4565	A	19861114 <--
			EP 1987-116251	A	19871104 <--

OTHER SOURCE(S): MARPAT 109:149535

GI



I



II

AB The title compds. [I; A = substituted 2-(imidazol-2-yl)ethyl, (un)substituted benzimidazolyl, benzothiazolyl, etc.; R, R2 = alkyl; R1 = halo; R3 = OH, alkoxy, alkanoyloxy, alkoxyalkanoyloxy, etc.; X = C1-18 alkylene, optionally interrupted by 1,4-phenylene or -cyclohexylene; n = 0, 1] were prepared PhCH2O2CNMe(CH2)3CONHC6H4NH2-2 (preparation given) was refluxed 2 h in PhMe containing 4-MeC6H4SO3H and the product hydrogenolized over Pd/C to give 2-[3-(methylamino)propyl]benzimidazole which was heated 30 min at 120° in (Me2CH)2NEt with 2-(6-fluoro-1,2,3,4-tetrahydro-2-hydroxy-1α-isopropyl-2β-naphthyl)ethyl p-toluenesulfonate to give title compound II (R3 = OH). The latter was stirred overnight with MeOCH2COCl in CHCl3 containing (Me2CH)2NEt to give II (R3 = MeOCH2CO2) (III) which, at 0.3 mg/kg i.v., gave 25% and 86% increase in heart contractility and coronary blood flow, resp., in anesthetized dogs. Tablets were prepared each containing III 75, lactose 135, starch 70, Povidone K 30 15, talc 3, and Mg stearate 2 mg.

IT **116643-65-3P 116643-66-4P 116644-10-1P**
116644-16-7P 116644-17-8P 116644-18-9P
116644-23-6P 116644-53-2P 116666-60-5P
116666-63-8P 116666-82-1P 116666-89-8P
116666-90-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as cardiovascular agent)

RN 116643-65-3 HCAPLUS

CN Acetic acid, methoxy-, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methyloxidoamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, [1S-[1α,2α,2(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116643-66-4 HCAPLUS
CN Acetic acid, methoxy-, 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methyloxidoamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, [1S-[1α,2α,2(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116644-10-1 HCAPLUS
CN Propanoic acid, 2-methyl-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116644-16-7 HCAPLUS
CN 2-Naphthalenol, 6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-[2-[methyl[3-(1-methyl-4,5-diphenyl-1H-imidazol-2-yl)propyl]amino]ethyl]-, (1S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116644-17-8 HCAPLUS
CN Acetic acid, methoxy-, 6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-[2-[methyl[3-(1-methyl-4,5-diphenyl-1H-imidazol-2-yl)propyl]amino]ethyl]-2-naphthalenyl ester, (1S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116644-18-9 HCAPLUS
CN Acetic acid, methoxy-, 6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-[2-[methyl[3-(1-methyl-4,5-diphenyl-1H-imidazol-2-yl)propyl]amino]ethyl]-2-naphthalenyl ester, dihydrochloride, (1S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 116644-23-6 HCAPLUS
CN Acetic acid, methoxy-, 2-[2-[[3-(4,5-diphenyl-1H-imidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride, (1S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 116644-53-2 HCAPLUS
CN Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.